Entrada Therapeutics(TRDA) - 2025 Q2 - Earnings Call Presentation

Clinical Programs & Pipeline - Entrada Therapeutics expects to have four active clinical-stage programs by the end of 2025[7, 17] - ENTR-601-44 is currently dosing patients in the UK and EU and is authorized in the US[7] Data from Cohort 1 of the ELEVATE-44-201 study is expected in the first half of 2026[3, 38] - ENTR-601-45 patient study is currently enrolling in the UK and EU, with first patient dosing expected in Q3 2025 and initial data from the first patient cohort expected in mid-2026[3, 7, 41] - Global regulatory filings for ENTR-601-50 are on track for submission in Q4 2025, and for ENTR-601-51 in 2026[3, 7, 42] - Vertex's DM1 program, VX-670, has an ongoing MAD portion of its global Phase 1/2 study to evaluate safety and efficacy, with completion of enrollment and dosing expected in H1 2026[7, 18] Financial Position - The company reports a cash balance of approximately $354 million as of June 30, 2025[8] - This cash balance is expected to provide a runway into Q2 2027[3, 8, 60] EEV Platform & Technology - The company's Endosomal Escape Vehicle (EEV) technology achieves approximately 50% endosomal escape, compared to a standard of approximately 2%[12] - EEV therapies demonstrate approximately 90% cellular uptake[13] ENTR-601-44 Phase 1 Data - The ENTR-601-44-101 study showed strong clinical safety up to 6 mg/kg, with no treatment-related adverse events reported[21, 22] - Favorable target exposure and engagement were observed at 6 mg/kg, with statistically significant exon skipping versus placebo[30, 33]